Work

GenAI and Statistics

Year: 2026
Type: article
Abstract: Presentation given at the Basel Biometric Society Annual Meeting 2026: Quantitative drug development in the age of AI. Abstract: Use of Generative AI is very common in many domains of specialized expertise, including biostatistics. However, applying GenAI to produce high-quality results in a specialized field - particularly within the high-stakes, regulated environment of the pharmaceutical industry - is far from straightforward. In this presentation, I will discuss practical approaches for using GenAI and agentic tools effectively. Different use cases bring distinct gains and risks. At one end, GenAI can be remarkably effective at strengthening the technical foundations of a project - adding checks, linting, formatting, automated tests, and version control - at low risk and cost. At the other end, when we ask AI to solve complex problems within a specialized domain, meaningful human oversight becomes considerably more difficult. Strong human-in-the-loop controls demand a systematic, deliberate approach across the full workflow - from planning to execution - together with the ability to observe and interpret an agent's actions, judge the reliability of its output, and apply the right technical capabilities, including appropriate skills, tools, agents, and agent harnesses. Developing both the technical skills to use GenAI and a clear understanding of use-case scenarios and their associated risks is essential. Doing so allows us to treat AI as a capable tool and thought partner rather than an opaque black box, and to generate results for which we can confidently take accountability.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7236099690
FWCI:
Cites:
Cited by:
Related to: 10